Drug intelligence / Profile preview

BM-R06

Development stage: Preclinical
Lead developer: Shenzhen Beimei Pharmaceutical

Overview

BM-R06 is a preclinical-stage drug candidate being developed by Bainei Pharmaceutical (also known as Beimei Pharma) for the treatment of infectious diseases. It is currently categorized within the company's anti-infection pipeline. As of the latest public disclosures, specific details regarding the drug's chemical structure, modality (such as small molecule or biologic), and biological target or mechanism of action have not been released.

Beyond the preview

Go deeper on BM-R06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM-R06.

Explore the full profile